Drug Profile
Research programme: selectin antagonists - Revotar
Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Revotar Biopharmaceuticals
- Class Small molecules
- Mechanism of Action Selectin inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Acute lung injury; Chronic obstructive pulmonary disease; Psoriasis
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Acute-lung-injury in Germany (Inhalation, Inhalant)
- 16 Jul 2016 No recent reports of development identified for preclinical development in Acute-lung-injury in Germany (IV)
- 16 Jul 2016 No recent reports of development identified for preclinical development in Acute-lung-injury in Germany (PO)